0001571049-16-014798.txt : 20160610 0001571049-16-014798.hdr.sgml : 20160610 20160504163015 ACCESSION NUMBER: 0001571049-16-014798 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncobiologics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 271603062 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 CORRESP 1 filename1.htm

May 4, 2016

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:	Suzanne Hayes

Re:	Oncobiologics, Inc.
	Registration Statement on Form S-1
	File No. 333-209011

	Acceleration Request
	Requested Date:	May 5, 2016
	Requested Time:	4:00 p.m., Eastern Time

Ladies and gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Jefferies LLC and Barclays Capital Inc., as representatives of the several underwriters, hereby join Oncobiologics, Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-209011) to become effective on Thursday, May 5, 2016, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter.

Additionally, pursuant to Rule 460 of the Act, we hereby advise you that the Preliminary Prospectus dated April 27, 2016, was distributed by us, as representatives of the several underwriters, approximately as follows from April 27, 2016 through the date hereof:

Copies to underwriters	661
Copies to dealers	0
Copies to institutional investors	588
Copies to others/retail	5
Total	1,254

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

Very truly yours,

JEFFERIES LLC

BARCLAYS CAPITAL INC.,

As Representatives

[Signature Page Follows]

	JEFFERIES LLC

	By:	/s/ Matthew Kim
		Name: Matthew Kim
		Title: Managing Director

	BARCLAYS CAPITAL INC.

	By:	/s/ Victoria Hale
		Name: Victoria Hale
		Title: Vice President

cc:	Pankaj Mohan, Ph.D., Oncobiologics, Inc.
	Lawrence A. Kenyon, Oncobiologics, Inc.
	Stuart M. Cable, Goodwin Procter LLP
	Edwin O’Connor, Goodwin Procter LLP
	Seo Salimi, Goodwin Procter LLP
	Yvan-Claude Pierre, Cooley LLP
	Daniel I. Goldberg, Cooley LLP
	Marianne Sarrazin, Cooley LLP

[signature page to acceleration request letter]